InDex, Almirall deal

The companies terminated a 2014 deal granting Almirall European rights to develop and commercialize Kappaproct. InDex, which now holds worldwide rights to the program, said the termination was due to Almirall’s R&D repositioning, which is shifting its focus to new chemical entities in dermatology. InDex said it plans to begin a clinical trial of Kappaproct by year end or early 2016. ...